A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW‐GRADE B‐CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.82_2629
Abstract: lets >40,000/μL, adequate renal and hepatic function and no significant cardiac disease. Growth factors, transfusion and anticoagulation were allowed. The primary efficacy endpoint was objective response using 2007 International Working Group criteria. Results: As of… read more here.
Keywords: cll; cell; response; cll sll ... See more keywords
Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3248-2
Abstract: Dear Editor, Accumulating evidence suggests that monoclonal B cell lymphocytosis (MBL) is a precursor condition for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/ SLL). Other MBL-derived B cell malignancies are quite rare, and the clonal evolution… read more here.
Keywords: cell; mbl; plasma cell; cll sll ... See more keywords
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04753-7
Abstract: Dear Editor, Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is an indolent form of small mature B-cell leukemia that predominantly affects older individuals [1]. In the World Health Organization (WHO) classification, CLL and SLL are… read more here.
Keywords: cll; treatment; leukemia; cll sll ... See more keywords
Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer genetics"
DOI: 10.1016/j.cancergen.2021.10.003
Abstract: Richter transformation (RT) refers to the development of an aggressive lymphoma in patients with pre-existing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It carries a poor prognosis secondary to poor response to therapy or rapid disease… read more here.
Keywords: patients richter; chromosomal microarray; transformation; richter transformation ... See more keywords
Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct158
Abstract: Background: Patients (pts) with CLL/SLL who use unmutated IGHV (u-CLL) have a less favorable outcome with standard chemotherapy than pts who use mutated IGHV (m-CLL). Ibrutinib (ibr) inhibits B-cell receptor signaling through Bruton’s tyrosine kinase… read more here.
Keywords: cll; ibr; comp; unmutated ighv ... See more keywords
Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113905
Abstract: Background The selective BCL2 inhibitor venetoclax (Ven) achieves an overall response rate of approximately 75 - 80% as a single agent in patients (pts) with relapsed and refractory chronic lymphocytic leukemia / small lymphocytic lymphoma… read more here.
Keywords: research; funding; pts cll; research funding ... See more keywords
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-127343
Abstract: Introduction: Duvelisib (DUV), an oral inhibitor of PI3K-δ/γ, and venetoclax (VEN), an oral inhibitor of BCL-2, are both approved for relapsed/refractory (R/R) CLL. We previously found that PI3K-δ inhibition sensitizes CLL cells to ex vivo… read more here.
Keywords: gr3; cll sll; consultancy; research funding ... See more keywords
A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130784
Abstract: INTRODUCTION: CG-806 is a first-in-class, oral, non-covalent, and potent inhibitor of the wild type and all known mutant forms of Bruton's tyrosine kinase (BTK, including the C481S mutation), as well as all forms of the… read more here.
Keywords: trial; safety; tolerability; sll non ... See more keywords
Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2019001160
Abstract: Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open--label, multicenter, phase1 study, patients in part 1 (3+3) dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40,… read more here.
Keywords: cll; inhibitor; cell malignancies; efficacy ... See more keywords
Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2019001795
Abstract: Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second generation oral… read more here.
Keywords: lymphoma; sll follicular; cll sll; sll ... See more keywords
Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps7581
Abstract: TPS7581Background: Inhibition of Bruton’s tyrosine kinase (BTK) has emerged as a strategy for targeting B-cell malignancies including CLL/SLL. Zanubrutinib has been shown to be a novel 2nd-generati... read more here.
Keywords: cll; zanubrutinib bgb; 3111 bendamustine; phase zanubrutinib ... See more keywords